With the use of gene-editing technology

We aim to repair the genetic blueprint of human cell

Changing the function of the cell to decrease chances of illness and to save human lives

Scroll to discover more or jump to "Why Choose Us?"
Loading animation...

Genome in our cells strongly defines our health and disease

Advances in synthetic biology enable us to correct errors that cause disease using CRISPR/Cas gene editing technology

We have invented an enhancement of CRISPR/Cas gene editing technology that improves the efficiency of gene editing for

  1. Preparation of KO cell lines, animals/plants
  2. Therapeutic gene targeting

We create advanced therapeutic solutions to help people with several gene-related health conditions

We focus in the fields of immuno-oncology with potentials for other genetic disorders

What are the advances of this technology

70% vs. 25% in benchmarked target gene inactivation*

Improved DNA recession and increased efficiency of gene inactivation with no additional increase in off-target effects and no cytotoxicity

*Depending on gene of interest

Our improvement of the CRISPR system offers new therapeutic and cell-editing opportunities. 

LABIOTECH.eu named CRISPR as one of the four technologies that will change cancer treatment.

Clara Rodriguez Fernandez

Our Technology

The core of our strategy is to couple Cas9 to the exonuclease to promote deletions at the specific target genomic site that prevents the repair of non-modified DNA. The best efficiency is achieved by using noncovalent coupling through coiled-coil dimers, developed previously by the Jerala group. Improved efficiency of target gene inactivation is one of the key applications of CRISPR, such as targeting dominant pathogenic mutations in primary cells for therapy or biotechnological applications. This is reflected in our portfolio and applications, notably immune-oncology conditions where we focused our interest.

H1 Dlainscek

One of the main inventors, dr. Duško Lainšček

Product pipeline

Field of Work  ›  Application
  • Discovery
  • Mode-of-Action
  • Preclinical
  • IND-Application
  • Phase 1
  • Phase 2
  • Phase 3
European Research Council